Researchers sought to identify health care system factors that contribute to missed or delayed diagnosis of dementia by primary care providers.
The FDA has approved Tauvid for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles.
A study found a causally protective effect of tobacco smoking on the risk of Parkinson disease.
The FDA has granted Fast Track designation to arimoclomol (Orphazyme A/S) for the treatment of amyotrophic lateral sclerosis.
This sublingual film formulation of apomorphine was designed for use as a fast-acting, on-demand treatment for all types of motor off episodes.
Given the limited data is available on bone health of patients with NMOSD-AQP4, researchers aimed to investigate their risk for fracture and bone loss.
A study finds that a majority of patients with Parkinson disease report difficulties in achieving early detection of their disease.
A subset of patients at risk for Alzheimer disease because of systemic inflammation may benefit from receiving a tumor necrosis factor blocking agent.
The risk for AD among patients with psoriasis was significantly increased in psoriasis patients not receiving systemic therapy compared with those receiving systemic therapy.
Many cognitive tests can differentiate clinical Alzheimer-type dementia from normal cognition.